Catumaxomab (formerly marked by Fresenius Biotech, Munich, Germany) was developed and approved as a targeted therapy for the i.p. treatment of malignant ascites in cancers expressing the epithelial cell-adhesion molecule (EpCAM).6 The gene discussed is EPCAM; the disease is cancer.